Gemtuzumab Ozogamicin 3mg/m 2 vs 6mg/m 2 (day 1 course 1) ADE vs DA DA (Daunorubicin 90mg/m 2 ) vs DA (Daunorubicin 60mg/m 2 ) Lestaurtinib vs not (FLT3 mutant) Everolimus vs not (courses 2-4) 3 vs 4 courses in total (if not high risk) FLAG-Ida vs Daunorubicin/Clofarabine
Supplementary Figure 2: Plasma Inhibitory activity (PIA) Measurement.
The protocol requested, with patient agreement, the collection of blood samples pre-dose on day 14 of each course of everolimus treatment. To assess mTOR inhibitory activity, 400μl patient plasma was incubated in triplicate with 5x10 5 HEL cells for 1h at 37°C in a humidified incubator with 5%CO2. The approach was similar to those reported for other inhibitory assays. 18 A standard curve of phospho-S6 ribosomal protein (pS6-RP) PIA versus everolimus concentration was generated by spiking healthy volunteer plasma with everolimus that produce clinically-relevant concentrations ranging from 1 to 200ng/ml. In this context an estimate of plasma inhibition of phospho-S6 ribsomal protein (p S6-RP) in response to patient plasma was measured in cell lysates by immunoblotting and ELISA. The results were expressed as a percentage reduction of pS6-RP inhibitory activity compared to the maximum inhibition achieved by a 200ng/ml everolimus concentration which was run in parallel along with a no drug control.
Overall survival from Everolimus randomization: Inhibition at all vs not at all timepoints (1+ timepoints measured)

Supplementary Figure 3: Resolution of Sanger data with AML17 mTOR randomisation (n=124)
Mutations in the following genes were found in only one patient and are not shown in the graph: 
